21 May 2015 
EMA/CHMP/324690/2015 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Fycompa 
perampanel 
On 21 May 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Fycompa. 
The marketing authorisation holder for this medicinal product is Eisai Europe Ltd. 
The CHMP adopted a new indication as follows: 
"Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult 
and adolescent patients from 12 years of age with idiopathic generalised epilepsy." 
For information, the full indications for Fycompa will be as follows: 
“Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily 
generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. 
Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures 
in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
